ClinicalTrials.gg

Program

samelisant

Also written as “SUVN-G3031” and “Samelisant”.

Its studies are mostly in Cataplexy · Cognitive Dysfunction, led by Suven Life Sciences.

Furthest: phase 3, since Apr 13, 20263 company-led studies, 1 open or runningNext primary completion: Nov 19, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Suven Life Sciences31 open or runningphase 3since Apr 13, 2026Aug 18, 2016Nov 19, 2027phase 3 · NCT07540364

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 18, 2016First study: phase 1 study in Cognitive DysfunctionFirst studyNCT02881294 · 24 enrolled · United States
  2. Aug 26, 2019Phase 2 study in NarcolepsyNCT04072380 · 190 enrolled · United States, Canada
  3. Apr 13, 2026Phase 3 study in NarcolepsyPhase 3 reachedNCT07540364 · 240 planned · United States

Ahead

  1. Nov 19, 2027Primary completion: phase 3 study in NarcolepsyNCT07540364

TargetBeta

HRH3 →read by rule
“Histamine H3 receptor inverse agonist”ChEMBL 37, by rule

Other programs on HRH3

ProgramCompanyFurthest phaseStudies
pitolisantruleHarmony Biosciencesphase 38

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07540364Narcolepsy · United States3RecruitingNov 19, 2027240
NCT04072380Narcolepsy · United States, Canada2CompletedJun 7, 2023190
NCT02881294Cognitive Dysfunction · United States1CompletedSep 201724

How it is read

Names in the registry

  • “SUVN-G3031”, 2 entries
  • “Samelisant”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.